Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fengwei Tan

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
American Journal of Respiratory and Critical Care Medicine|July 28, 2022
Risk-stratified Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in ChinaFei Wang, Fengwei Tan, Sipeng Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
International Journal of Epidemiology|September 7, 2023
Ethnic differences of genetic risk and smoking in lung cancer: two prospective cohort studiesMeng Zhu, Jun Lv, Yanqian Huang, et al.
Gut|February 14, 2014
LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinomaJiagen Li, Zhaoli Chen, Liqing Tian, et al.
The Lancet. Respiratory Medicine|March 11, 2022
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort studyNi Li, Fengwei Tan, Wanqing Chen, et al.
Eclinicalmedicine|August 4, 2022
Uptake of lung cancer screening with low-dose computed tomography in China: A multi-centre population-based studyWei Cao, Fengwei Tan, Kuangyu Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2020
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Ning Li, Shunyu Gao, et al.
Molecular Cancer|June 11, 2022
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detectionHua Bao, Zheng Wang, Xiaoji Ma, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 5, 2021
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer]Jun Ni, Miao Huang, Li Zhang, et al.
Cell|March 27, 2025
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerZedao Liu, Zhenlin Yang, Junqi Wu, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
American Journal of Respiratory and Critical Care Medicine|July 28, 2022
Risk-stratified Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in ChinaFei Wang, Fengwei Tan, Sipeng Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
International Journal of Epidemiology|September 7, 2023
Ethnic differences of genetic risk and smoking in lung cancer: two prospective cohort studiesMeng Zhu, Jun Lv, Yanqian Huang, et al.
Gut|February 14, 2014
LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinomaJiagen Li, Zhaoli Chen, Liqing Tian, et al.
The Lancet. Respiratory Medicine|March 11, 2022
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort studyNi Li, Fengwei Tan, Wanqing Chen, et al.
Eclinicalmedicine|August 4, 2022
Uptake of lung cancer screening with low-dose computed tomography in China: A multi-centre population-based studyWei Cao, Fengwei Tan, Kuangyu Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2020
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Ning Li, Shunyu Gao, et al.
Molecular Cancer|June 11, 2022
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detectionHua Bao, Zheng Wang, Xiaoji Ma, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 5, 2021
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer]Jun Ni, Miao Huang, Li Zhang, et al.
Cell|March 27, 2025
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerZedao Liu, Zhenlin Yang, Junqi Wu, et al.
Pageof 16